PRKCI and diabetic kidney disease: To further explore the potential molecular mechanism of the protective effect of EchA in diabetic nephropathy in vivo, the activity of the PKCι/p38 MAPK pathway and its downstream targets, such as p53 and c-Jun, was examined.